BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35916204)

  • 21. Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition.
    Zhang Y; Zhang J; Liang S; Lang G; Liu G; Liu P; Deng X
    J BUON; 2019; 24(5):2090-2098. PubMed ID: 31786880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly expressed long non-coding RNA FEZF1-AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer.
    Zhu LF; Song LD; Xu Q; Zhan JF
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5122-5132. PubMed ID: 31298365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
    Wang D; Zheng Y
    Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway.
    Tuo Z; Zhang J; Xue W
    Biochem Biophys Res Commun; 2018 May; 499(4):875-881. PubMed ID: 29625110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA KTN1-AS1 promotes progression in pancreatic cancer through regulating microRNA-23b-3p/high-mobility group box 2 axis.
    Zhang ZB; Liu N
    Aging (Albany NY); 2021 Aug; 13(16):20820-20835. PubMed ID: 34461605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long non-coding RNA AFAP1-AS1 promotes proliferation and invasion in prostate cancer via targeting miR-512-3p.
    Wang K; Sun H; Sun T; Qu H; Xie Q; Lv H; Hu B
    Gene; 2020 Feb; 726():144169. PubMed ID: 31669642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long non-coding RNA ZEB2-AS1 expression is associated with disease progression and predicts outcome in gastric cancer patients.
    Xu C; Cui H; Li H; Wu Y; An H; Guo C
    J BUON; 2019; 24(2):663-671. PubMed ID: 31128021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
    Ma D; Chen C; Wu J; Wang H; Wu D
    Breast Cancer; 2019 Jan; 26(1):74-83. PubMed ID: 29974352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/β-catenin signaling pathway.
    Wang ZY; Hu M; Dai MH; Xiong J; Zhang S; Wu HJ; Zhang SS; Gong ZJ
    Mol Cancer; 2018 Jan; 17(1):3. PubMed ID: 29310682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA ADAMTS9-AS1, as prognostic marker, promotes cell proliferation and EMT in colorectal cancer.
    Chen W; Tu Q; Yu L; Xu Y; Yu G; Jia B; Cheng Y; Wang Y
    Hum Cell; 2020 Oct; 33(4):1133-1141. PubMed ID: 32918700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53.
    Luo X; Zhou N; Wang L; Zeng Q; Tang H
    Can J Gastroenterol Hepatol; 2019; 2019():1389653. PubMed ID: 31871924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer.
    Lv Y; Li H; Li F; Liu P; Zhao X
    Cancer Biother Radiopharm; 2017 Apr; 32(3):91-99. PubMed ID: 28414551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer.
    Yan H; Li H; Silva MA; Guan Y; Yang L; Zhu L; Zhang Z; Li G; Ren C
    J Exp Clin Cancer Res; 2019 Aug; 38(1):356. PubMed ID: 31412903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of LncRNA AFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer.
    Ma F; Wang SH; Cai Q; Zhang MD; Yang Y; Ding J
    Biomed Pharmacother; 2016 Dec; 84():1249-1255. PubMed ID: 27810781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in Osteosarcoma.
    Ye H; Lin J; Yao X; Li Y; Lin X; Lu H
    Cell Physiol Biochem; 2018; 45(5):1904-1914. PubMed ID: 29518771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceramide synthase 6 antisense RNA 1 contributes to the progression of breast cancer by sponging miR-16-5p to upregulate ubiquitin-conjugating enzyme E2C.
    Pan W; Chen KJ; Huang YC
    Anticancer Drugs; 2022 Oct; 33(9):913-922. PubMed ID: 36136991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo.
    Wang Q; Yang L; Hu X; Jiang Y; Hu Y; Liu Z; Liu J; Wen T; Ma Y; An G; Feng G
    Oncotarget; 2017 Jan; 8(2):3441-3453. PubMed ID: 27966450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis.
    Zhang YT; Li BP; Zhang B; Ma P; Wu QL; Ming L; Xie LM
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6333-6341. PubMed ID: 30338801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.